Abstract
Development of Mycobacterium tuberculosis attenuated strains as live vaccine candidates for tuberculosis
Highlights
Tuberculosis (TB) is an infectious disease caused mainly by the bacillus Mycobacterium tuberculosis
Two major strategies have been used to develop new vaccine candidates against TB: (i) substitution of BCG in which an improved version of BCG or a new attenuated live M. tuberculosis vaccine would have a higher efficiency than BCG and replace it as a prime vaccine; and (ii) a prime-boost strategy in which BCG continues to be given to neonates, and a new vaccine is given as a booster dose
The strategy to develop novel vaccines based on the construction of rationally attenuated M. tuberculosis strains holds the advantage of potentially eliciting a more sustained protective immune response than viral vectored and recombinant protein candidates
Summary
Tuberculosis (TB) is an infectious disease caused mainly by the bacillus Mycobacterium tuberculosis. Numerous vaccine candidates against TB are currently in preclinical and clinical trials, including recombinant BCGs, attenuated M. tuberculosis strains, recombinant viral-vectored platforms, protein/adjuvants combinations and mycobacterial extracts [1]. The strategy to develop novel vaccines based on the construction of rationally attenuated M. tuberculosis strains holds the advantage of potentially eliciting a more sustained protective immune response than viral vectored and recombinant protein candidates.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call